Oncology

Volume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Seek %0-9
00:00
00:00
00:00
 

Chapters

Transcript

Video

An Open-Label, Multicenter, Phase IIIb Study of Patients with Urinary Tract Carcinoma (UTC) (STRONG): Final Analysis for Fixed-Dose Durvalumab Monotherapy (Module A)

Bladder Cancer: Guru Sonpavde, MD details STRONG study results presented at ASCO #GU21? that find fixed-dose durvalumab monotherapy safe in patients previously treated for urinary tract carcinoma. Abstract 429

Related Presenters

Guru P. Sonpavde, MD.

Guru P. Sonpavde, MD

Medical Oncology

View Profile

ADVERTISEMENT

Related Videos

Phase 2 Study of the Oral Hypoxia-Inducible Factor 2a (HIF-2a) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) Video

Phase 2 Study of the Oral Hypoxia-Inducible Factor 2a (HIF-2a) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

The Very Favorable Metastatic Renal Cell Carcinoma (mRCC) Risk Group: Data From the International Metastatic RCC Database Consortium (IMDC) Video

The Very Favorable Metastatic Renal Cell Carcinoma (mRCC) Risk Group: Data From the International Metastatic RCC Database Consortium (IMDC)

Impact of FGFR2/3 Activating Genomic Alterations on Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma (mUC) Video

Impact of FGFR2/3 Activating Genomic Alterations on Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma (mUC)

Post-Radical Prostatectomy (RP) Outcome for Patients with High-Risk Prostate Cancer Treated with Intense Neoadjuvant Hormone Therapy (NHT): Results of a Pooled Analysis of Contemporary Clinical Trials Video

Post-Radical Prostatectomy (RP) Outcome for Patients with High-Risk Prostate Cancer Treated with Intense Neoadjuvant Hormone Therapy (NHT): Results of a Pooled Analysis of Contemporary Clinical Trials

Analysis of Plasma KIM-1 as a Biomarker for Recurrence Risk After Resection for Localized Renal Cell Carcinoma Video

Analysis of Plasma KIM-1 as a Biomarker for Recurrence Risk After Resection for Localized Renal Cell Carcinoma

Phase 3 Trial of Lenvatinib (LEN) Plus Pembrolizumab (PEMBRO) or Everolimus (EVE) Versus Sunitinib (SUN) Monotherapy as a First-Line Treatment for Patients (pts) with Advanced Renal Cell Carcinoma (RCC) (CLEAR Study Video

Phase 3 Trial of Lenvatinib (LEN) Plus Pembrolizumab (PEMBRO) or Everolimus (EVE) Versus Sunitinib (SUN) Monotherapy as a First-Line Treatment for Patients (pts) with Advanced Renal Cell Carcinoma (RCC) (CLEAR Study